首页> 外文OA文献 >1951. Nephrotoxicity Associated With Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients With Imipenem-Nonsusceptible (NS) Bacterial Infections

【2h】

1951. Nephrotoxicity Associated With Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients With Imipenem-Nonsusceptible (NS) Bacterial Infections

机译：1951.与Imipenem / Cilastatin / Creebactam（IMI / Rel）相关的肾毒性，伊皮思 - 非肌肉（NS）细菌感染患者癌症患者

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Michelle Brown; Johann Motsch; Keith Kaye; Thomas File; Helen W Boucher; Neika Vendetti; Angela Aggrey; Hee-Koung Joeng; Robert Tipping; Jiejun Du; Daryl D Depestel; Joan Butterton; Nicholas A Kartsonis; Amanda Paschke;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Evaluation of Renal Safety Between Imipenem/Relebactam and Colistin Plus Imipenem in Patients With Imipenem-Nonsusceptible Bacterial Infections in the Randomized, Phase 3 RESTORE-IMI 1 Study [J] . Michelle L Brown, Johann Motsch, Keith S Kaye, Open Forum Infectious Diseases . 2020,第3期

机译：在随机化，第3期恢复-IMI 1研究中，IMIPENEM / Creebactam和Colistin Plus Imipenem对癌症患者的肾脏安全性评估
2. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections [J] . Sims Matthew, Mariyanovski Valeri, McLeroth Patrick, The Journal of Antimicrobial Chemotherapy . 2017,第9期

机译：预期，随机，双盲，相2剂量测量研究比较伊翅尼/氯斯坦加蛋白质/含有IMIPENEM / Cilastatin的疗效和安全性在复杂的泌尿道感染患者中的疗效和安全性
3. Imipenem/cilastatin sodium/relebactam fixed combination to treat urinary infections and complicated intra-abdominal bacterial infections [J] . Thakare R., Dasgupta A., Chopra S. Drugs of today: Medicamentos de actualidad . 2020,第4期

机译：Imipenem / Cilastatin钠/重新纳米固定组合治疗尿感染和复杂的腹内细菌感染
4. 1951. Nephrotoxicity Associated With Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients With Imipenem-Nonsusceptible (NS) Bacterial Infections [O] . Michelle Brown, Johann Motsch, Keith Kaye, -1

机译：1951年。对亚胺培南-不敏感（NS）细菌感染的患者亚胺培南/西拉他汀/雷巴坦（IMI / REL）与亚胺培南/西拉他汀加共清单蛋白（IMI + CST）相关的肾毒性
5. Evaluation of Renal Safety Between Imipenem/Relebactam and Colistin Plus Imipenem in Patients With Imipenem-Nonsusceptible Bacterial Infections in the Randomized, Phase 3 RESTORE-IMI 1 Study [O] . Michelle L Brown, Johann Motsch, Keith S Kaye, 2020

机译：在随机化，第3期恢复-IMI 1研究中，IMIPENEM / Creebactam和Colistin Plus Imipenem对癌症患者的肾脏安全性评估

1951. Nephrotoxicity Associated With Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients With Imipenem-Nonsusceptible (NS) Bacterial Infections

著录项

相似文献

相关主题

期刊订阅